Cagrilintide
Also known as: Cagrilintide, AM833
Cagrilintide is a long-acting amylin analog developed for weight management, often paired with semaglutide. It slows gastric emptying and increases satiety to reduce food intake.
Last updated
Mechanism of Action
Cagrilintide is an acylated, long-acting analog of the pancreatic hormone amylin that acts as a non-selective agonist at amylin and calcitonin receptors (AMY receptors formed by the calcitonin receptor plus RAMP proteins). Activation of these receptors in the area postrema and hypothalamus slows gastric emptying, suppresses glucagon secretion, and enhances satiety signaling, lowering caloric intake. The fatty-acid acylation enables albumin binding for a prolonged, once-weekly pharmacokinetic profile. When combined with GLP-1 agonism (e.g., in CagriSema), it produces complementary, additive appetite suppression.
- Half-life
- Approximately 7-9 days, supporting once-weekly administration
- Administration Routes
- subcutaneous
- Research Status
- Clinical
Reported Benefits
- Significant appetite suppression and reduced caloric intake
- Clinically meaningful weight loss, especially with semaglutide (CagriSema)
- Slows gastric emptying to prolong satiety
- Once-weekly dosing from long half-life
- Improves markers of glycemic control
- Complementary mechanism to GLP-1 receptor agonists
Potential Side Effects
- Nausea, especially during dose escalation
- Vomiting and diarrhea
- Constipation and reduced appetite
- Injection-site reactions
- Possible hypoglycemia when combined with other glucose-lowering agents
Common Dosing
For research use only and not medical advice: clinical trials have used once-weekly subcutaneous doses titrated up to about 2.4 mg, frequently combined with semaglutide 2.4 mg.
The dosing information above is aggregated from research literature and anecdotal community reports for educational purposes only. It is not a recommendation, prescription, or medical advice. Peptides are sold as research chemicals only and are not intended for human use.
Contraindications
- Personal or family history of medullary thyroid carcinoma or MEN2 (precautionary, class-related)
- Pregnancy and breastfeeding
- History of severe gastrointestinal disease or gastroparesis
GLP-3 R
GLP-3 R is an investigational triple agonist that simultaneously activates the GLP-1, GIP, and glucagon receptors, studied for substantial weight loss and improved glycemic control. It is one of the most potent incretin-based agents in late-stage clinical development.
Tesofensine
Tesofensine is a triple monoamine reuptake inhibitor originally developed for neurodegenerative disease and later investigated as an anti-obesity drug. It produces appetite suppression and notable weight loss in clinical trials. Note: Tesofensine is a small-molecule triple monoamine reuptake inhibitor, not a peptide, but is sold alongside metabolic research compounds.
5-Amino-1MQ
5-Amino-1MQ is a small-molecule inhibitor of the enzyme NNMT, studied in animal models for its potential to reduce fat storage and support metabolic health.
- View
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
2021
- View
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
2023
- View
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
2025
- View
Development of Cagrilintide, a Long-Acting Amylin Analogue
2021